Frederic Dayan
Overview
Explore the profile of Frederic Dayan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
1410
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lereclus A, Welzel J, Belzeaux R, Korchia T, Dayan F, Blin O, et al.
J Psychopharmacol
. 2024 Sep;
38(12):1054-1062.
PMID: 39344032
Background: Treatment optimization is mandatory in psychiatric diseases and the use of population pharmacokinetics (popPK) models through model informed precision dosing (MIPD) has the potential to improve patient medical care....
2.
Aurelie L, Andrea B, Gauvind K, Olivier B, Raoul B, Dayan F, et al.
Pharmaceuticals (Basel)
. 2023 Nov;
16(11).
PMID: 38004492
Lithium has been used in the treatment of bipolar disorder for several decades. Treatment optimization is recommended for this drug, due to its narrow therapeutic range and a large pharmacokinetics...
3.
Koloskoff K, Benito S, Chambon L, Dayan F, Marquet P, Jacqz-Aigrain E, et al.
Eur J Clin Pharmacol
. 2023 Oct;
80(1):83-92.
PMID: 37897528
Introduction: Mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF), is widely used in the treatment of systemic lupus erythematosus (SLE). It has been shown that its therapeutic drug...
4.
Llopis-Lorente J, Baroudi S, Koloskoff K, Mora M, Basset M, Romero L, et al.
Comput Methods Programs Biomed
. 2023 Oct;
242:107860.
PMID: 37844488
Background And Objective: In silico methods are gaining attention for predicting drug-induced Torsade de Pointes (TdP) in different stages of drug development. However, many computational models tended not to account...
5.
Lereclus A, Korchia T, Riff C, Dayan F, Blin O, Benito S, et al.
Ther Drug Monit
. 2022 Apr;
44(5):674-682.
PMID: 35385439
Background: Therapeutic drug monitoring and treatment optimization of clozapine are recommended, owing to its narrow therapeutic range and pharmacokinetic (PK) variability. This study aims to assess the clinical applicability of...
6.
Grenet I, Merlo K, Comet J, Tertiaux R, Rouquie D, Dayan F
J Chem Inf Model
. 2019 Feb;
59(4):1486-1496.
PMID: 30735402
The development of in silico tools able to predict bioactivity and toxicity of chemical substances is a powerful solution envisioned to assess toxicity as early as possible. To enable the...
7.
Pez F, Dayan F, Durivault J, Kaniewski B, Aimond G, Le Provost G, et al.
Cancer Res
. 2011 Jan;
71(5):1647-57.
PMID: 21239473
Adaptation to hypoxia is a driving force for tumor progression that leads to therapy resistance and poor clinical outcome. Hypoxic responses are mainly mediated by hypoxia-inducible transcription factor-1 (HIF-1). One...
8.
Dayan F, Mazure N, Brahimi-Horn M, Pouyssegur J
Cancer Microenviron
. 2009 Mar;
1(1):53-68.
PMID: 19308685
The hypoxia-inducible factor is the key protein responsible for the cellular adaptation to low oxygen tension. This transcription factor becomes activated as a result of a drop in the partial...
9.
Dayan F, Monticelli M, Pouyssegur J, Pecou E
J Theor Biol
. 2009 Mar;
259(2):304-16.
PMID: 19298827
Unlabelled: Hypoxia Inducible Factor (HIF), being the master protein involved in adaptation to low pO(2), plays a major role in many physiological and pathological phenomena: development, inflammation, ischemia and cancer....
10.
Chiche J, Ilc K, Laferriere J, Trottier E, Dayan F, Mazure N, et al.
Cancer Res
. 2009 Jan;
69(1):358-68.
PMID: 19118021
Acidosis of the tumor microenvironment is typical of a malignant phenotype, particularly in hypoxic tumors. All cells express multiple isoforms of carbonic anhydrase (CA), enzymes catalyzing the reversible hydration of...